The current state of hormonal therapy for prostate cancer.
about
AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progressionHormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerAdministration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environmentTargeting Bone Metastases in Metastatic Castration-Resistant Prostate CancerHistone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trialsThe role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancerDNA-Repair Defects and Olaparib in Metastatic Prostate CancerThe importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistanceAbiraterone and increased survival in metastatic prostate cancerAsymmetric synthesis and evaluation of a hydroxyphenylamide voltage-gated sodium channel blocker in human prostate cancer xenograftsEffectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program.HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancerEfficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea.The role of GATA2 in lethal prostate cancer aggressiveness.Integrin involvement in freeze resistance of androgen-insensitive prostate cancer.Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC-MS/MS-ESI: application to a pharmacokinetic study.Caffeic acid phenethyl ester causes p21 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells.Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.Development and validation of an enantioselective LC-MS/MS method to quantify enantiomers of (±)-TAK-700 in rat plasma: lack of in vivo inversion of (+)-TAK-700 (Orteronel) to its antipode.Validated RP-HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats.Diethylstilboestrol for the treatment of prostate cancer: past, present and future.The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred DiethylstilbestrolDevelopment and validation of an RP-HPLC method for the quantitation of Orteronel (TAK-700), a CYP17A1 enzyme inhibitor, in rat plasma and its application to a pharmacokinetic study.Protective effect of carboxymethyl-glucan (CM-G) against DNA damage in patients with advanced prostate cancer.3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity.Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235)Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression.Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cellsCombinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort.Identification of beta-2 as a key cell adhesion molecule in PCa cell neurotropic behavior: a novel ex vivo and biophysical approach.Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate CancerAndrogen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.Testosterone depletion or blockade in male rats protects against trauma hemorrhagic shock-induced distant organ injury by limiting gut injury and subsequent production of biologically active mesenteric lymphCaffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
P2860
Q21203668-15F91F83-791B-4F4E-8CA9-7815369923E7Q24646000-41E46482-6748-4647-8B0C-2224B3E363FDQ25255562-06AE69C3-3CBD-499F-A192-FC1065D06132Q26752785-86F2FD0A-D84E-4A5B-AA37-C3854525088EQ26775761-AA084A1C-783D-493B-AECD-A484CF5F5A1AQ26823733-F8A5D989-697D-4707-872C-99D3A084D674Q27853235-B02EB1B4-6DED-41E8-9FEE-B084CCDD37DBQ28076745-85E6F44A-647B-45DC-B6E7-380058667C4FQ29617512-8600D253-6A49-4635-B120-910875A078C7Q30411740-06D9C633-DCB4-4709-8154-CF4961F24650Q30847864-C82BEB15-666C-43C1-8142-753BAF764043Q33623369-5D54D368-8A01-492A-8FA5-D76B9305B5C7Q33647321-5DE457CA-11B9-4F42-AA42-0EE77FACB3AEQ33682922-08C34C65-187F-4497-BE3B-DE45298537C0Q33766472-64BE16EF-2EB5-4FAA-AF58-2CF90A1D454BQ33848134-44B73FAB-BB6D-4837-8071-AA135568DB17Q33848813-69A9C43D-48E0-4514-B16B-3A258C50F466Q34048805-10BD564E-C8FE-4240-AB39-DE858FC5AA99Q34162761-D67BE03E-8CAB-4156-9D6A-51B7630122F6Q34278855-F3F74BA9-46F0-486A-A688-4B6FE1124024Q34291736-CF0C33EE-AC4A-4AF6-B14C-4C1FC88778CAQ34310115-B2547F84-8D13-4ECE-A8B5-1C642113409CQ34327168-890C4209-BE65-4DA5-A5C5-3E17BFF905E1Q34386403-5DB4ABA7-558C-44EA-90FC-5FB93E5E1813Q34522279-9B0125D9-0D20-4D89-8980-4D2BDD8273D8Q34627994-8E07E099-A70D-41AE-A8B7-FE60991FB682Q34779973-0A3526B9-BE9B-4553-8245-AE910C15844AQ34896779-2DB65748-FF05-4A28-8315-A9423CD6C320Q34956743-21033109-B5AC-48A5-BE94-BDBC573DBEF9Q34972660-2F7D1949-575F-4F00-BF1F-8A7CDCD09A53Q35042220-C2E2FED6-87F0-40CA-BF45-FFE05B9EC1FCQ35070404-DE0FCBAD-033F-4776-95F0-07B8837AD81FQ35080706-69558847-0D35-4322-B65D-62E3C7930AC3Q35161023-5BBAA665-607E-4045-A76A-BBD9F17B2B55Q35180664-0583F031-DA3C-4AB6-B423-2F1105978C1BQ35210730-D911114A-0514-44F7-93BB-1BA9C61737A6Q35434843-BB4D3D2F-0DAC-40E2-A90A-46BBF0F62435Q35683334-5E54CAE1-A790-471D-88EB-A22853FBF1FDQ35719745-9C5E6C8F-5C13-4AB9-AC9D-4CCD9275176DQ35740051-211C630B-3862-4FCE-ACF9-D128D2D8B450
P2860
The current state of hormonal therapy for prostate cancer.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The current state of hormonal therapy for prostate cancer.
@ast
The current state of hormonal therapy for prostate cancer.
@en
The current state of hormonal therapy for prostate cancer.
@nl
type
label
The current state of hormonal therapy for prostate cancer.
@ast
The current state of hormonal therapy for prostate cancer.
@en
The current state of hormonal therapy for prostate cancer.
@nl
prefLabel
The current state of hormonal therapy for prostate cancer.
@ast
The current state of hormonal therapy for prostate cancer.
@en
The current state of hormonal therapy for prostate cancer.
@nl
P1433
P1476
The current state of hormonal therapy for prostate cancer.
@en
P2093
Beth A Hellerstedt
Kenneth J Pienta
P304
P356
10.3322/CANJCLIN.52.3.154
P407
P577
2002-05-01T00:00:00Z